The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Alopecia Totalis & Alopecia Universalis

Severe forms of autoimmune hair loss — total scalp hair loss (totalis) and complete body hair loss (universalis) — with significant psychological impact and emerging targeted therapies.

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dermatoloji department. Book Appointment →

What is Alopecia Totalis & Alopecia Universalis?

Alopecia totalis and universalis represent the most severe ends of the alopecia areata spectrum, an autoimmune disease where T cells attack anagen hair follicles via interferon-γ and IL-15 signaling. AT involves complete scalp hair loss (>95%), while AU extends to all body terminal and vellus hair.

Pathogenesis: collapse of hair follicle immune privilege, MHC class I overexpression, NKG2D ligand upregulation on follicular keratinocytes, and JAK-STAT-mediated cytotoxic T cell activation. Genetic susceptibility loci include HLA, ULBP3/6, IL-2RA. Triggers: viral infection, stress, vaccination, hormonal change.

Clinical course: AT/AU may evolve from patchy alopecia areata over months to years, or develop rapidly. Spontaneous regrowth is rare (<10% in long-standing cases). Associated conditions: thyroid autoimmunity, vitiligo, atopic dermatitis, type 1 diabetes. Quality-of-life impact is profound, with high rates of anxiety and depression.

Symptoms

Complete loss of scalp hair (alopecia totalis)
Loss of eyebrows, eyelashes, beard, axillary, pubic, and body hair (alopecia universalis)
Smooth, non-scarring scalp without inflammation
Possible nail changes: pitting, trachyonychia, longitudinal ridging
Tingling or burning sensation before hair loss
Yellow dots, exclamation mark hairs at active borders (rarely visible in AT/AU)
Significant psychological distress, social anxiety, depression

Risk Factors

Family history of alopecia areata or autoimmune disease
Personal history of atopy, asthma, or thyroid disease
Onset of patchy AA in childhood (poorer prognosis)
Ophiasis pattern (band-like temporo-occipital loss)
Long-standing AA >5 years
Severe initial extent (SALT score >50)
Comorbid Down syndrome, vitiligo, type 1 diabetes

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Rapid progression of patchy hair loss to >50% scalp involvement
  • Loss of eyebrows or eyelashes — early intervention may improve prognosis
  • Severe psychological distress, depression, suicidal ideation — urgent mental health support
  • Complete loss of body hair without identifiable cause — endocrine and dermatologic workup
  • Failure of topical therapy after 6 months — systemic therapy consideration

Treatment Methods

01
JAK inhibitors (transformative): oral baricitinib 4 mg daily (FDA-approved 2022), ritlecitinib 50 mg, deuruxolitinib 8 mg twice daily — regrowth in 30–50% at 36 weeks; continued therapy required to maintain response
02
Topical/intralesional corticosteroids: limited efficacy in AT/AU compared to patchy AA, occasional adjunct
03
Topical immunotherapy: diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester (SADBE) sensitization with weekly dilutions, 30–40% response in long-standing AT/AU
04
Systemic immunosuppressants: methotrexate, cyclosporine, azathioprine — modest efficacy with relapse on cessation
05
Pulse corticosteroid therapy: oral methylprednisolone or dexamethasone in early-onset disease, limited long-term benefit
06
Adjunctive: low-level laser therapy (LLLT), platelet-rich plasma (limited evidence in AT/AU)
07
Cosmetic and supportive: wig prescription, prosthetic eyebrows/eyelashes, scalp tattooing, sunscreen for scalp protection
08
Psychological support: cognitive behavioral therapy, support groups (NAAF), screening for anxiety and depression
09
Monitoring: thyroid function, lipid profile, complete blood count on JAK inhibitor therapy; opportunistic infection screening

Which Department to Visit?

You can visit our Dermatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dermatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Eczema (Atopic Dermatitis)

Dermatoloji

Atopic dermatitis is a chronic skin disease commonly seen especially in children, flaring with genetic predisposition and environmental triggers.

Psoriasis

Dermatoloji

Psoriasis is an autoimmune disease in which skin cells proliferate rapidly when the immune system mistakenly attacks the skin, leading to thick scaly lesions.

Acne

Dermatoloji

Acne is a skin disease resulting from clogging of hair follicles with oil and dead skin cells, commonly seen in adolescence but can occur at any age.

Rosacea

Dermatoloji

Rosacea is a chronic inflammatory facial skin disease characterized by recurrent flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules. Phymatous change and ocular involvement may complicate advanced disease.

Urticaria (Hives)

Dermatoloji

Urticaria is a skin condition with sudden pink-red wheals and intense itching that may follow an acute or chronic course.

Skin Fungal Infections

Dermatoloji

Skin fungal infections are common, contagious skin diseases caused by dermatophytes and yeast fungi colonizing the upper layers of the skin.

Hair Loss (Alopecia)

Dermatoloji

Alopecia is a general term for hair loss that can be genetic, hormonal, autoimmune, or nutritional; early intervention can slow progression.

Vitiligo

Dermatoloji

Vitiligo is an acquired autoimmune disease in which CD8+ T cells destroy melanocytes, producing well-demarcated depigmented patches. Early, sustained treatment can induce repigmentation and prevent progression; psychosocial impact warrants holistic care.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.